Early insight into the molecular pathogenesis of cancer stemmed from the discovery of activating oncogenes such as the Philadelphia chromosome positive (Ph+), and its constitutively active BCR-ABL protein tyrosine kinase product, in chronic myeloid leukemia (CML) [2–4]. The gene discussed is BCR; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.